---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-036496"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2021-07-14T23:59:59+00:00"
generated_at: "2026-06-30T05:29:14.327756+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Nkarta signs 12-year lease for 88,106 sq ft manufacturing and HQ facility in South San Francisco

## Summary
- Monthly base rent starts at ~$564K, escalating to ~$823K; tenant improvement allowance up to $25.2M.
- Facility will support research, development, and commercial manufacturing of NK cell therapy pipeline.
- Expected operational by end of 2023; planned production for pivotal trials and commercial launch.
- Nkarta retains existing 2,700 sq ft cGMP facility for early-stage clinical manufacturing.

## SEC filing metadata
- accession: 0001564590-21-036496
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2021-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000156459021036496/0001564590-21-036496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000156459021036496/nktx-8k_20210709.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-036496
- JSON: https://secwatch.observer/filing/0001564590-21-036496.json
- Plain text: https://secwatch.observer/filing/0001564590-21-036496.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.